SomaLogic, Inc., a leading clinical proteomics company, has entered a technology development agreement with Quest Diagnostics Incorporated, the leading provider of diagnostic testing, information and services in the US.
Under the terms of the agreement, Quest Diagnostics will develop new diagnostic tests based on SomaLogic's proprietary aptamer array platform. In addition, Quest Diagnostics has made a $15 million equity investment in SomaLogic. Additional terms of the agreements and timetables for test development were not disclosed.
SomaLogic is using its proprietary aptamer array technology to discover new biomarkers and patterns of biomarkers (or disease signatures) for a range of unmet needs in the area of clinical diagnostics. SomaLogic currently has active development programs in the areas of oncology, as well as cardiovascular, autoimmune, and infectious diseases. Quest Diagnostics will develop clinical diagnostic tests based on these biomarkers and disease signatures, stated a release.